BioNTech Results Presentation Deck

COVID-19 Vaccine Continued Success in 2022 2022 Order Book as of mid-March: 2.4Bn Doses Continued Label Expansion Global Manufacturing Network Preemptive Approach to Variants 12 Pediatrics • 5 to <12 yrs: ● ● Accomplishments Position Company for ● ● 6 mo to <5 yrs: Evaluating 3-dose regimen; data expected in April 2022 Data will be submitted to FDA and other regulators Obtained approvals in multiple markets¹ for 2-dose regimen for BNT 162b2 Evaluating third dose. ● Comprehensive variant-based vaccine development program Development of Omicron-based vaccine on track • Scaled up manufacturing and started production Boosters Obtained approvals in multiple markets¹ for BNT162b2 booster (3rd dose) in 12 yrs+ Building state-of-the-art mRNA manufacturing sites in Africa and Asia • BioN Tainers designed to enable rapid setup of new mRNA vaccine manufacturing nodes 1 Includes U.S., EU, Canada and other countries FDA approved 4th dose in 50 yrs+ and in 12 yrs+ with certain kinds of immunocompromise Evaluating 3rd or 4th dose of variant-based versus wild-type vaccines Generating clinical data to support potential regulatory submission; first data expected in April 2022 Comprehensive research program to investigate evolution of SARS-CoV-2 directed immunity under vaccinations and infections to inform further vaccine development InstaDeep collaboration to further develop early-warning system for high-risk variants BIONTECH

View entire presentation